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Abstract 
Systemic sarcoidosis is a disease of unknown etiology, with the liver being the third most 
commonly affected organ. Most cases of hepatic sarcoidosis are not clinically apparent, but 
a few can progress to liver cirrhosis, portal hypertension and ultimately liver failure. The 
diagnosis of hepatic sarcoidosis is difficult, considering that no single laboratory test or 
radiographic finding can definitively diagnose this systemic disease. Diagnosis of hepatic 
sarcoidosis relies heavily on histopathologic evaluation of two or more organs, a diagnostic 
modality that is invasive and may not be applicable to all patients. The treatment of hepatic 
sarcoidosis is challenging, with no large randomized controlled trials done to date. Physicians 
must be aware of the complications of hepatic sarcoidosis, and must include the same in the 
differential diagnosis of liver cirrhosis. We present a case of hepatic sarcoidosis complicated 
by portal hypertension and liver cirrhosis. 
 
Introduction 
Sarcoidosis is a systemic non-caseating granulomatous disease involving many 
organs [1]. The prevalence of sarcoidosis in the United States is reported to be 1–40 
per 100,000 with a three-fold higher risk in African Americans when compared to 
Caucasians [2, 3]. Furthermore, there is increasing evidence of more severe disease in  
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African Americans, with higher incidence of skin, eye, liver and bone marrow 
involvement.  
The typical manifestation of sarcoidosis is the presence of non-caseating 
granulomas, affecting the lungs and lymph nodes in more than 90% of cases, but it can 
involve any organ system [2, 4, 5]. The liver is the third most commonly involved organ 
after the lymph nodes and the lungs [3, 4, 6]. Most cases of hepatic involvement from 
sarcoidosis are clinically silent, with only a few patients developing jaundice, chronic 
cholestasis, portal hypertension and/or Budd-Chiari syndrome [1, 2]. Cirrhosis is a very 
rare complication of liver sarcoidosis found in less than 1% of cases [4, 7]. We present a 
case of granulomatous liver disease secondary to sarcoidosis complicated with portal 
hypertension and liver cirrhosis. 
Case Report 
A 48-year-old African American male with a medical history significant for idiopathic pulmonary 
fibrosis, hypertension, coronary artery disease and gout was seen in the gastroenterology clinic for 
complaints of abdominal pain. The patient stated that for nearly 2 weeks he had been noticing 
intermittent, dull, right upper quadrant pain that was neither alleviated nor aggravated by any 
factors. He stated that he had had a decrease in appetite over the last 2 weeks and reported a 
30 pound unintentional weight loss over the past 6 months. He denied the presence of any change in 
bowel habits, melena, hematemesis, vomiting, fever, chills or cough. He denied use of any tobacco, 
alcohol or recreational drugs. Family history was not significant, for the presence of any malignancy, 
gastrointestinal or pulmonary disorder. He was currently serving as a machine operator and did not 
report any hazardous occupational or environmental exposure.  
Physical examination revealed a frail man in no acute distress. Abdominal examination yielded 
mild right upper quadrant tenderness without any guarding or rigidity. The liver edge was 
approximately 2–3 cm below the right costal margin, and an enlarged spleen was palpable. There 
were no stigmata of any chronic liver disease. Complete blood count performed was remarkable for 
leukopenia of 2,000/mm3 and thrombocytopenia of 109,000/mm3. Also noted was an alanine 
transaminase of 71 IU/l and an aspartate transaminase of 75 IU/l, along with a markedly increased 
alkaline phosphatase of 898 IU/l. Due to the abnormal liver-related tests, a laboratory evaluation of 
possible infectious, autoimmune and malignant liver processes was done, all yielding negative results 
(table 1). A computed tomography (CT) of the abdomen revealed hepatosplenomegaly with dilated 
portal and splenic vessels, suggestive of portal hypertension.  
In consideration of the patient’s laboratory and radiographic findings, a CT-guided biopsy of the 
liver was performed. Histopathologic evaluation of the biopsy specimen revealed non-caseating 
granulomatous inflammation with moderate periportal fibrosis, consistent with hepatic sarcoidosis 
(fig. 1). Special staining for fungus and acid-fast bacilli was negative. A subsequent CT of the thorax 
demonstrated bronchiectatic changes scattered in the lungs along with peripheral honeycombing, 
ground glass opacities and subpleural nodules with no significant mediastinal or hilar adenopathy. 
These findings were unchanged from a previous CT of the thorax performed a year earlier. 
The patient was started on systemic steroids (prednisolone 0.5 mg/kg/day) which were continued 
for 6 weeks without improvement in clinical symptoms and liver tests. The patient was also referred 
for pulmonary evaluation to determine the presence of pulmonary sarcoidosis. Prior and recent CT 
thorax findings, laboratory values and pulmonary function testing were inconclusive for pulmonary 
sarcoidosis.  
Upon follow-up 6 weeks later, his alkaline phosphatase and liver transaminases remained 
elevated, along with the presence of worsening leukopenia. The patient also complained of continuous 
abdominal pain, which had worsened from the initial visit. He now stated both right and left upper 
quadrant pain, with the latter appearing to be more severe. With no significant response to systemic 
steroids he was referred for splenectomy secondary to worsening pancytopenia, hypersplenism and 
abdominal discomfort. Splenectomy was also thought to be beneficial for this patient, considering the  
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presence of portal hypertension in sarcoidosis. Gross examination of the spleen revealed it to be 
markedly enlarged, weighing approximately 990 g (fig. 2a). Histopathologic examination of the 
splenic tissue showed diffuse confluent non-caseating granulomas and foreign body giant cells 
containing polarized foreign bodies with some patchy areas of calcification, highly consistent with 
sarcoidosis (fig. 2b). Special staining for fungus and acid-fast bacilli was negative.  
After splenectomy, the patient continued to follow in hepatology, pulmonary and surgery clinics, 
and he displayed a marked improvement in his abdominal symptoms. A repeat CT scan of the 
abdomen 6 months later revealed mild diffuse heterogeneity of the liver parenchyma with diffuse 
nodularity of the liver contour, highly suggestive of cirrhosis (fig. 3). A small to moderate volume of 
complex ascites was also noted. With other causes of liver cirrhosis being excluded, a diagnosis of 
liver cirrhosis with portal hypertension secondary to hepatic sarcoidosis was made.  
The patient was started on a low sodium diet and diuretics, which resulted in resolution of his 
ascites. Due to the presence of cirrhosis, he underwent a screening esophagogastroduodenoscopy 
which did not reveal any gastroesophageal varices. A follow-up liver ultrasonography (US) and 
alpha-fetoprotein level to evaluate for the presence of hepatocellular carcinoma were both negative. 
The patient is currently being evaluated for possible liver transplantation.  
Discussion 
Extrathoracic sarcoidosis can occur with and without lung involvement. It is rare to 
find isolated extrapulmonary disease, which accounts for less than 10% of cases [4]. 
Hepatic sarcoidosis mostly affects the younger population group between 20 and 
40 years of age. Most of these lesions are usually asymptomatic, with only 5–30% 
presenting with atypical clinical signs and symptoms including nausea, vomiting, 
jaundice, abdominal pain and hepatosplenomegaly [2, 4]. A small portion of hepatic 
sarcoidosis can be severe and rapidly progressive, with the occurrence of complications 
such as cirrhosis, portal hypertension, chronic cholestasis and Budd-Chiari syndrome 
[2, 6]. The first report of portal hypertension associated with sarcoidosis was published 
in 1949 by Mino et al. [8], followed by Katskin in 1950 [9]. Since then, the incidence of 
sarcoidosis with portal hypertension and cirrhosis has gradually been increasingly 
reported [1]. Although half of patients with sarcoidosis may have portal hypertension 
without evidence of cirrhosis, early detection is crucial since the development of 
cirrhosis carries a poor prognosis [1].  
Hepatic sarcoidosis can also manifest as chronic cholestasis, which can either be 
intra- or extrahepatic in nature. Chronic intrahepatic sarcoidosis may resemble 
primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), and either 
of these two diseases can coexist with sarcoidosis [1, 6]. Sarcoidosis is usually 
differentiated from PBC by normal IgM levels and the absence of elevated 
anti-mitochondrial antibody, which is positive in nearly 90% of patients with PBC. 
Sarcoidosis is differentiated from PSC by the absence of inflammatory bowel disease, 
lack of periductal fibrosis in histology, absence of anti-nuclear cytoplasmic antibody, 
restriction of the narrowing of the bile duct to a single area of the biliary system, and 
improvement with steroid treatment [1].  
The pathophysiology of portal hypertension and cirrhosis in sarcoidosis is not 
completely understood and may involve multiple mechanisms. It has been suggested 
that small arterio-venous shunts may form in the region of the granulomas, resulting in 
an elevated portal blood flow which subsequently increases intrahepatic resistance 
[1, 3, 10]. Such resistance can also be increased by a large confluent of granulomas  
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caused by healing fibrosis of the parenchyma in a haphazard distribution. The 
development of portal central bridging fibrosis may ultimately lead to cirrhotic 
remodeling and development of portal hypertension [1, 5, 10]. Others suggest that the 
granulomas in the portal areas may produce pressure and restrict its normal flow, 
causing a perisinusoidal block [1, 11]. Another theory suggests that cirrhosis and focal 
fibrosis are caused by ischemic changes brought about by primary granulomatous 
phlebitis of portal and hepatic veins, thereby increasing pre- and postsinusoidal 
resistance [1, 5]. The pathogenesis of chronic intrahepatic cholestasis in sarcoidosis is 
due to destruction of bile ducts by portal and periportal granulomas that can ultimately 
lead to biliary cirrhosis [1].  
The diagnosis of hepatic sarcoidosis is clinically challenging, considering its wide 
spectrum of disease presentation and the absence of any specific symptoms, signs, 
laboratory or radiographic findings. No precise guidelines are available for the 
assessment and diagnosis of hepatic sarcoidosis to date. It has been suggested that 
the diagnosis is made by clinical and radiologic findings suggestive of sarcoidosis, 
supported by histopathologic findings of non-caseating granulomas on biopsy obtained 
from either the liver, after the exclusion of other causes of hepatic granuloma formation 
such as lymphoma, solid tumors, Wegener’s granulomatosis, PBC, farmer’s lung disease, 
drug reactions and occupational/environmental exposures [12]. 
Routine laboratory evaluation in sarcoidosis is often non-specific. Laboratory 
studies such as peripheral lymphopenia with CD4 depletion, elevated ACE level, 
lysozyme, B-2 microglobulin, hypercalcemia and hypercalcuria can aid in the diagnosis 
[4, 6]. Hepatic sarcoidosis usually demonstrates abnormal liver-related tests in 20–50% 
of cases, with alkaline phosphatase being most commonly affected [4, 5]. The degree of 
liver test abnormalities appears to be related to the degree of fibrosis and the degree of 
granulomatous inflammation [2]. 
Radiographic evaluation of abdominal sarcoidosis includes US, CT and magnetic 
resonance imaging (MRI) [13, 14]. Unlike thoracic sarcoidosis, which commonly 
presents with hallmark radiographic and CT findings of interstitial lung disease 
and mediastinal/hilar lymphadenopathy, no single imaging technique can accurately 
diagnose sarcoidosis in the abdomen [15]. US does not usually show hepatic or 
splenic focal sarcoidosis lesions, but it can demonstrate a non-specific increase in 
heterogeneity or echogenicity with organ enlargement, as well as the degree of 
fibrosis present in the granuloma [13, 16]. In a recent study by Cremers et al. 
[2], US has a sensitivity of 46.2% in detecting hepatic sarcoidosis and has a limited 
value in confirming the diagnosis. CT scan of the abdomen may reveal diffuse 
hepatosplenomegaly, but focal hepatic and splenic lesions are only seen in 38 and 33% 
of biopsy-proven cases, respectively [13]. Nodular hepatic sarcoidosis appears on CT as 
areas of multiple, low-attenuation lesions scattered throughout the liver, with no 
significant peripheral enhancement [16]. With MRI, the lesions are hyperintense on all 
sequences with lesser enhancement than the background liver parenchyma. These 
lesions are more conspicuous in gadolinium-enhanced MRI, which is considered 
superior to US and CT in the evaluation of abdominal sarcoidosis [13, 14]. 
The treatment of sarcoidosis with hepatic involvement remains controversial. The 
use of glucocorticoids may show some improvement of liver-related tests, but they do 
not alter the course and progression of the disease [1, 3, 12]. In our review of the  
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literature, the most widely accepted approach in the treatment of hepatic sarcoidosis 
involves the use of glucocorticoids in patients with symptomatic sarcoidosis and 
evidence of cholestasis or elevated liver transaminases [3, 12]. No treatment is 
necessary in asymptomatic patients [3, 12]. Other alternate drugs reportedly being 
used in sarcoidosis include azathioprine, methotrexate, hydrochloroquine and 
infliximab [12]. No large randomized trials have been done to assess the efficacy of 
these drugs, which is most likely related to the rarity of the disease process. Patients 
with portal hypertension are also being treated with splenectomy [1]. Other Indications 
for splenectomy in sarcoidosis include symptomatic splenomegaly, severe 
hypersplenism, prophylaxis for splenic rupture and exclusion of neoplastic processes 
[12]. In advanced sarcoidosis of the liver, transplantation is the only option considered 
curative [12]. 
Although rare, the development of liver cirrhosis in patients with sarcoidosis should 
be considered in the differential diagnosis of cryptogenic cirrhosis. Clinicians should be 
aware of complications from hepatic sarcoidosis, as progression to cirrhosis harbors a 
poor prognosis. 
 
 
 
Table 1. Laboratory evaluation of possible infectious, autoimmune 
and malignant liver processes 
        Laboratory test  Result (normal) 
        Hepatitis B surface antigen  non-reactive 
Hepatitis B core IgM antibody  non-reactive 
Hepatitis B core antibody, total  non-reactive 
Hepatitis B surface antibody, mIU/ml  12 (>10, immunity) 
Hepatitis A antibody IgM  non-reactive 
Hepatitis A antibody, total  non-reactive 
HCV antibody screening  non-reactive 
Anti-mitochondrial antibodies  negative 
Anti-smooth muscle antibodies  negative 
Alpha-1-antitrypsin, mg/dl  173 (83–199) 
Iron, μg/dl  56 (45–160) 
Transferrin saturation, %  18 (20–55) 
Ceruloplasmin, mg/dl  47 (18–36) 
Alpha-fetoprotein, serum tumor marker, ng/ml  2.1 (<6.1) 
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Fig. 1. Liver biopsy revealing the presence of a non-caseating granuloma (arrow) with epitheloid 
cells. 
 
 
 
Fig. 2. a Enlarged spleen with multiple nodular pattern typical of sarcoidosis. b Microscopic specimen 
of the spleen revealing multiple non-caseating granulomas (arrows) composed of epitheloid cells and 
multi-nuclear giant cells. 
 
  
Case Rep Gastroenterol 2012;6:183–189 
DOI: 10.1159/000338355 
Published online: 
April 18, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
 
189 
 
Fig. 3. CT scan of the abdomen. Note the diffuse heterogeneity of the liver parenchyma with diffuse 
nodularity of the liver contour (arrows), highly suggestive of liver cirrhosis. Mild ascites was also 
noted (arrowhead). 
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